Alliance Pharma plc provided earnings guidance for the second half of 2023. For the period, The company anticipates strong growth in H2 as Kelo-Cote revenues continue to build, the company recommence supply of products that have been out of stock and launch new product innovation. The Board's expectation for Group year-end performance remains unchanged.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.95 GBX | +0.14% | -5.16% | -13.70% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.70% | 235M | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- APH Stock
- News Alliance Pharma plc
- Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023